Tyra Biosciences’ Q4 Review
<p><a href='https://financialmodelingprep.com/financial-summary/TYRA'>Tyra Biosciences, Inc. (NASDAQ:TYRA)</a> reported its Q4/22 results yesterday. According to CEO Alan Fuhrman, the company is starting off 2023 in a very favorable financial position. As of the end of 2022, the company had $251.2 million in cash and cash equivalents, which is more than enough to support its ongoing development plans across its precision medicine platform for over two years.</p>
<p>Last week, analysts at Oppenheimer hosted the company at their healthcare conference, where management shared thoughts about the company’s recent decision to expand TYRA-300's development into achondroplasia—as well as their expectations for the recently initiated SURF301 trial. </p>
<p>The analysts came away with greater conviction in the scope of TYRA-300's potential market opportunity, which they believe is probably underappreciated, given middling sales from pan-FGFR inhibitors (e.g., erdafitinib) in metastatic urothelial carcinoma (mUC). </p>
<p>Unlike erdafitinib, TYRA-300 was designed to dial out off-target toxicities, which the analysts believe could not only translate to better efficacy in mUC—but could also make the case for expansion into earlier lines of treatment and non-oncology indications (e.g., achondroplasia).</p>

NASDAQ:TYRA